Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I apologize

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Aug 19, 2021 9:31pm

180 Views

Post# 33737993

RE:I apologize

Rarbar99 wrote: Looking back that was very distasteful lol. Most of y'all lost 70%+ of your investments this month and some new kid showed up and flexed a quarter million dollar car on yall. Oof. but to be fair, yall kept insulting me so you kinda asked for it.

In that first photo of the dash with the piece of paper on the console are you by any chance the 25 year old waitress shown beneath it -- with the red car? Oh -- no, I guess not - you said you are 22.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages